GCG and type 2 diabetes mellitus: The more favourable side-effect profile and ease of administration of DPP-4 inhibitors compared with GLP-1 agonists suggest that DPP-4 inhibitors will be better tolerated; however, the emerging evidence of superior cardiovascular outcomes with the use of GLP-1 agonists in T2DM indicates that larger-scale trials of both DPP-4 inhibitors and GLP-1 agonists in the treatment of PTDM are warranted.